Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic trioxide added to induction chemotherapy for non-M3 acute myeloid leukemia
IRCT20140818018842N16Phase 3Completed
- Sponsor
- Hematology, Oncology and Stem Cell Transplantation Research Center
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of arsenic trioxide in acute myeloid leukemia (AML) (2 arms), sponsored by Hematology, Oncology and Stem Cell Transplantation Research Center. Primary endpoint: Complete Remission. Started Dec 2017; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on IRCT20140818018842N16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140818018842N16.